Foamix Pharmaceuticals Ltd. (FOMX) financial statements (2021 and earlier)

Company profile

Business Address 2 HOLZMAN ST.
REHOVOT, 76704
State of Incorp.
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:72756982998812
Cash and cash equivalents44413919288812
Short-term investments28343063712142
Other undisclosed cash, cash equivalents, and short-term investments     (21)(42)
Restricted cash and investments1111111
Receivables0 01111
Inventory, net of allowances, customer advances and progress billings1      
Inventory1      
Derivative instruments and hedges, assets   0(0)  
Other undisclosed current assets212112343
Total current assets:7677728510111256
Noncurrent Assets
Operating lease, right-of-use asset2222
Property, plant and equipment3322222
Long-term investments and receivables    012
Long-term investments    012
Restricted cash and investments 000000
Other noncurrent assets0000000
Total noncurrent assets:5554334
TOTAL ASSETS:8182769010411560
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities28121394915
Accounts payable197960512
Accrued liabilities3543043
Employee-related liabilities5   3  
Debt1111   
Other undisclosed current liabilities0   6  
Total current liabilities:291314910915
Noncurrent Liabilities
Long-term debt and lease obligation331411   
Long-term debt, excluding current maturities3313     
Operating lease, liability1111
Other undisclosed noncurrent liabilities1111111
Total noncurrent liabilities:341522111
Total liabilities:64281612121016
Stockholders' equity
Stockholders' equity attributable to parent185460789210544
Common stock3322222
Additional paid in capital325324308306305304228
Accumulated other comprehensive income (loss)00(0)0(0)(0)(0)
Accumulated deficit(311)(273)(250)(231)(215)(201)(186)
Total stockholders' equity:185460789210544
TOTAL LIABILITIES AND EQUITY:8182769010411560

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Gross profit:0  0111
Operating expenses(38)(23)(19)(16)(16)(16)(20)
Operating loss:(37)(23)(19)(16)(15)(16)(19)
Interest and debt expense (0)     
Other undisclosed loss from continuing operations before equity method investments, income taxes(1)      
Loss from continuing operations before equity method investments, income taxes:(38)(23)(19)(16)(15)(16)(19)
Other undisclosed income from continuing operations before income taxes1001000
Loss from continuing operations before income taxes:(38)(23)(19)(15)(14)(15)(19)
Income tax expense (benefit)   00(0)(0)
Net loss available to common stockholders, diluted:(38)(23)(19)(15)(14)(15)(19)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(38)(23)(19)(15)(14)(15)(19)
Comprehensive loss:(38)(23)(19)(15)(14)(15)(19)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent00(0)000 
Comprehensive loss, net of tax, attributable to parent:(38)(23)(19)(15)(14)(15)(19)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: